Table 3. Comparison of medication use among patients during 2019 vs 2020.

Data is summarized using the mean ± standard deviation (SD) and the median with interquartile range (Q1-Q3). * Wilcoxon signed-ranks test significant at p<0.05

Medication Use	N	Mean ± SD	Median(Q1-Q3)	p-value
Dose of Beta2 agonist 2019	262	2.7±1.0	2(2-4)	0.06
Dose of Beta2 agonist 2020	280	2.6±0.9	2(2-4)
Frequency of Beta2 agonist 2019	314	4.0 ±1.5	4(4-4)	0.38
Frequency of Beta2 agonist 2020	311	4.0 ±1.3	4(4-4)
Dose of steroid inhaler 2019	272	1.8 ±0.5	2(2-2)	0.93
Dose of steroid inhaler 2020	267	1.8 ±0.6	2(2-2)
Frequency of steroid inhaler 2019	271	2.0 ±0.3	2(2-2)	0.84
Frequency of steroid inhaler 2020	269	2.0 ±0.3	2(2-2)
Dose of leukotriene inhibitors 2019	171	4.6 ±1.0	5(4-5)	<0.001*
Dose of leukotriene inhibitors 2020	163	4.9 ±1.0	5(5-5)
Frequency of leukotriene inhibitors 2019	171	1.0 ±0.1	1(1-1)	1
Frequency of leukotriene inhibitors 2020	162	1.0 ±0.0	1(1-1)
Dose of oral steroids 2019	97	13.9 ±6.5	12(10-16)	0.38
Dose of oral steroids 2020	50	14.3 ±7.8	14(8.8-16.5)